Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011;16(4):388-403.
doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26.

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Heinz Ludwig  1 , Meral Beksac, Joan Bladé, Jamie Cavenagh, Michele Cavo, Michel Delforge, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Jean-Luc Harousseau, Urs Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen-Nativ, Larisa Mendeleeva, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Pieter Sonneveld, Miklos Udvardy, Pia Sondergeld, Antonio Palumbo
Affiliations
Review

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Heinz Ludwig et al. Oncologist. 2011.

Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Heinz Ludwig: Honoraria: Celgene, Ortho Biotech, Mundipharma; Research funding/contracted research: Celgene, Ortho Biotech, Mundipharma; Meral Beksac: Consultant/advisory role: Celgene; Honoraria: Celgene, Janssen-Cilag, Novartis; Joan Bladé: None; Jamie Cavenagh: None; Michele Cavo: None; Michel Delforge: Honoraria: Celgene, Janssen-Cilag; Research funding/contracted research: Celgene, Janssen-Cilag; Meletios Dimopoulos: Honoraria: Celgene, Ortho Biotech, Novartis; Johannes Drach: Consultant/advisory role: Janssen-Cilag, Mundipharma; Honoraria: Celgene, Janssen-Cilag, Mundipharma; Hermann Einsele: Consultant/advisory role: Celgene, Janssen-Cilag, Novartis; Honoraria: Celgene, Janssen-Cilag, Novartis; Research funding/contracted research: Celgene, Janssen-Cilag, Novartis; Thierry Facon: Consultant/advisory role: Janssen, Celgene; Hartmut Goldschmidt: Consultant/advisory role: Celgene, Janssen, Mundipharma; Honoraria: Celgene, Janssen, Mundipharma; Research funding/contracted research: Celgene; Jean-Luc Harousseau: Consultant/advisory role: Celgene, Janssen, Novartis, Onyx, Bristol-Myers Squibb; Honoraria: Celgene, Janssen; Urs Hess: Consultant/advisory role: Janssen, Celgene; Martin Kropff: Honoraria: Ortho Biotech, Celgene; Fernando Leal da Costa: Consultant/advisory role: MSD, Janssen, Celgene; Honoraria: Janssen, Celgene, Amgen; Vernon Louw: Research funding/contracted research: Janssen; Hila Magen-Nativ: None; Larisa Mendeleeva: None; Hareth Nahi: None; Torben Plesner: None; Jesús San-Miguel: Consultant/advisory role: Millennium, Celgene, Janssen, Novartis; Honoraria: Millennium, Celgene, Janssen, Novartis; Pieter Sonneveld: Honoraria: Janssen, Celgene, Onyx; Research funding/contracted research: Janssen, Celgene, Onyx; Miklos Udvardy: None; Pia Sondergeld: None; Antonio Palumbo: Consultant/advisory role: Celgene, Janssen-Cilag; Honoraria: Celgene, Janssen-Cilag, Merck, Amgen.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Figures

Figure 1.
Figure 1.
Multiple myeloma treatment tree outside clinical trials: frontline. aIndicates data available from phase III randomized trial. Lenalidomide is currently not EMA approved for the treatment of newly diagnosed multiple myeloma or as consolidation or maintenance treatment. Bortezomib is currently not EMA approved for the treatment of transplant-eligible patients or as consolidation or maintenance treatment. Thalidomide is currently not EMA approved for the treatment of transplant eligible patients or as consolidation or maintenance treatment. Abbreviations: CR, complete response; CTD, cyclophosphamide, thalidomide, and dexamethasone; CTDa, attenuated cyclophosphamide, thalidomide, and dexamethasone; MP, melphalan and prednisone; MPR + R, melphalan, prednisone, and lenalidomide plus lenalidomide maintenance; MPT, melphalan, prednisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PN, peripheral neuropathy; Pred, prednisone; Rd, lenalidomide plus low-dose dexamethasone; RD, lenalidomide and dexamethasone; TAD, thalidomide, doxorubicin, and dexamethasone; Thal, thalidomide; TT3, Total Therapy 3; VCD, bortezomib, cyclophosphamide, and dexamethasone; VDT-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide; VGPR, very good partial response; VMP, bortezomib, melphalan, and prednisone; VMPT-VT, bortezomib, melphalan, prednisone,and thalidomide followed by maintenance with bortezomib and thalidomide; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone.
Figure 2.
Figure 2.
Multiple myeloma treatment tree outside clinical trials: relapse. aIndicates data available from phase III randomized trial. bRetreatment with bortezomib after frontline bortezomib only if no PN is present, or if PN has recovered and there is no other therapeutic alternative. Abbreviations: ASCT, autologous stem cell transplantation; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; Dex, dexamethasone; IMiD, immunomodulatory drug; Len, lenalidomide; MPT, melphalan, prednisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PegLD, pegylated liposomal doxorubicin; PN, peripheral neuropathy; Thal, thalidomide; VCD, bortezomib, cyclophosphamide, and dexamethasone; VD, bortezomib and dexamethasone; VMP, bortezomib, melphalan, and prednisone; VMPT, bortezomib, melphalan, prednisone, and thalidomide; VTD, bortezomib, thalidomide, and dexamethasone.
See this image and copyright information in PMC

References

    1. Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: A European perspective. The Oncologist. 2010;15:6–25. - PMC - PubMed
    1. van de Velde HJK, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–1406. - PubMed
    1. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–5782. - PubMed
    1. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114:3139–3146. - PubMed
    1. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–2624. - PubMed

Publication types